Novartis AG





Market Closed - Swiss Exchange 11:30:19 2024-06-12 EDT 5-day change 1st Jan Change
94.66 CHF +0.62% Intraday chart for Novartis AG +2.08% +11.54%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
NOVARTIS AG : JP Morgan reiterates its Neutral rating ZD
Abu Dhabi, Novartis to Collaborate on Genomics Research for Cancer Therapy MT
Novartis, Roche's Genentech Among Companies Facing Italian Competition Watchdog Inquiry Over Eye Drug MT
AlphaValue/Baader Europe Lowers Price Target on Novartis, Maintains Add Recommendation MT
Staff at drugmaker under U.S. scrutiny worked with Chinese military scientists RE
Novartis, Roche, Biogen, Samsung Bioepis in Italy Eye-Medicine Probe DJ
Novartis and others face Italy antitrust probe over eye drug RE
Cytokinetics CEO Says Board Would Have Backed Actionable Buyout DJ
The odds of rates getting cut in 2024 may be better than you think Our Logo
NOVARTIS AG : Deutsche Bank maintains a Buy rating ZD
Bank Vontobel Lifts Price Target on Novartis, Maintains Buy Recommendation MT
NOVARTIS AG : JP Morgan remains Neutral ZD
NOVARTIS AG : Buy rating from Goldman Sachs ZD
NOVARTIS : UBS reiterates buy recommendation after ASCO CF
NOVARTIS AG : UBS gives a Buy rating ZD
Pre-surgery treatment with Bristol Myers combination therapy leads to better skin cancer outcomes RE
NOVARTIS AG : UBS reiterates its Buy rating ZD
European Equities Close Higher in Friday Trading; Flash Euro Area Inflation Rises More Than Expected MT
Swiss Market Index in the Green Amid US Rate Cut Optimism MT
NOVARTIS AG : Jefferies remains its Buy rating ZD
Novartis Says Late-Stage Scemblix Trial Meets Primary Endpoints MT
Novartis Says New Data Show Long-term Efficacy, Safety of Potential Urticaria Therapy MT
Novartis Blood Cancer Drug Scemblix Meets Main Goals of Late-stage Study MT
Novartis: positive trial results in chronic myeloid leukemia CF
Novartis Blood Cancer Drug Scemblix Meets Main Goals of Late-stage Study MT
Chart Novartis AG
More charts
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
104.7 USD
Average target price
110.2 USD
Spread / Average Target
  1. Stock Market
  2. Equities
  3. NOVN Stock
  4. News Novartis AG
  5. Sector Update: Health Care Stocks Retreat Thursday Afternoon